CLL Society Inc.

CLL Society is a 501(c)(3) nonprofit meeting the unmet needs of those living with #CLL and #SLL.

[CLL Society Inc. @CllSociety]

One month until Celebrating Long Lives! Registration is almost closed, grab your virtual spot and be a part of a team.

If you've been thinking about joining us on September 26th, now's the time.

Walk with friends and family and be part of a community supporting CLL/SLL patients and care partners.

Register now: https://t.co/FJdlN0ljzT

#CelebratingLongLives #CLLS5K #CLL #SLL

[CLL Society Inc. @CllSociety]

Adding early #Obinutuzumab to #Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve #CLL.

https://t.co/i59yJwMqvX

[CLL Society Inc. @CllSociety]

New patient resource, developed with @DeceraClinEdu: understanding today's CLL/SLL treatment options and preparing for shared decision-making with your care team.

Learn more: https://t.co/tk63N2vpJS

#CLL #SLL

[CLL Society Inc. @CllSociety]

Join CLL Society's Celebrating Long Lives 5K on September 26th.

As a virtual walk event, you can participate your way. Walk with friends, walk with family, walk solo. Every participant supports our mission to improve the lives of those impacted by CLL/SLL through education, support, and research.

Register to walk: https://t.co/FJdlN0kLKl
#CelebratingLongLives #CLLS5K #CLL #SLL

[CLL Society Inc. @CllSociety]

The experimental BCL-2 inhibitor, lisaftoclax, was well-tolerated and had a beneficial effect in patients with CLL / SLL, and the combination of lisaftoclax plus acalabrutinib seems very effective and offers the convenience of a five-day versus the five-week ramp-up of venetoclax.
https://t.co/pU6D5wmRPv

[Ohio State Hematology @OSUHematology]

Way-to-go @KerryARogersMD! Dr. Rogers is awarded a Clinical Scholar Award for CLL Research- supports clinical research aimed at improving care & outcomes for patients w/ CLL. Her project: “Overcoming CLL Resistance to Targeted Agents Through Rational Combination.” @OSUCCC_James

[CLL Society Inc. @CllSociety]

Have you signed up for Celebrating Long Lives yet?

September 26th, walk at your own pace from anywhere, and support patients and care partners affected by CLL/SLL. Registration is open and we'd love to have you join us.

Sign up today: https://t.co/FJdlN0ljzT
#CelebratingLongLives #CLLS5K #CLL #SLL

[CLL Society Inc. @CllSociety]

This year, CLL Society's Research Program is proud to announce two prestigious researchers for the Clinical Scholar Award and the Young Investigator Award.

Each of these awards supports innovative research aimed at enhancing treatment options specifically for individuals living with CLL/SLL.

Our 2026 Research Program Awards are:
Clinical Scholar Award

Kerry Rogers, MD from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Young Investigator Award

António Ferreira, PhD from Brigham and Women’s Hospital and Harvard Medical School

The growth of CLL Society's Research Program is made possible by our generous donors. Thank you for your support.

Read about our awardees: https://t.co/0brMRpUn7v

Learn more about what we fund: https://t.co/Gb8JB3K1cc

#CLL #CLLSociety2026ResearchAwards #ClinicalScholarAward #YoungInvestigatorAward

[CLL Society Inc. @CllSociety]

How are Part D plans responding to changes in Medicare, and what can your office do when coverage is denied or delayed?

On August 12, two policy and access experts take both questions on. Saira Sultan, JD, President and CEO of Connect 4 Strategies and Director of Government Affairs and Public Policy at CLL Society, and Kay Scanlan, JD, Principal at Consilium Strategies, will share practical steps healthcare providers can use to navigate coverage barriers, plus how to alert advocacy organizations to the systemic obstacles your office faces.

Have a coverage challenge you keep running into? Submit it in advance by Monday, August 10 and the moderator may put it to our speakers. Please keep questions clear and broadly relevant, and leave out personal medical details.

Hosted with the Association of Cancer Care Centers (@ACCCBuzz).

Register: https://t.co/WLOW2xLSNW

Submit a question: https://t.co/AQDhDesJgd

#CLL #Oncology #PatientAccess #MedicarePartD

[CLL Society Inc. @CllSociety]

When a Part D plan decides which CLL therapy your patient can access, the deciding factor isn’t always clinical.

A Part D plan can make it decidedly easier or harder to prescribe one medication over another, and those decisions are sometimes grounded in financial considerations rather than clinical ones.

Join CLL Society and the Association of Cancer Care Centers (ACCC) on Wednesday, August 12 for a 60-minute webinar built for CLL care teams. Saira Sultan, JD and Kay Scanlan, JD will cover how Part D plans may be responding to changes in Medicare, what you and your staff can do to minimize disruptions and delays when coverage is denied or delayed, and how to alert advocacy organizations to the systemic barriers your office faces.

You will leave with steps you can use the next time a coverage decision threatens the treatment your patient needs.

12 PM ET. Registration is open.

Register: https://t.co/WLOW2xLSNW

#CLL #Oncology #MedicarePartD #PatientAccess

[CLL Society Inc. @CllSociety]

MRD-guided ibrutinib plus venetoclax is an effective combination therapy for treating CLL and can provide durable responses.

https://t.co/7o3C8shTA5

#CLL #SLL #CLLSociety

[CLL Society Inc. @CllSociety]

Patients with double-refractory disease, which is resistant to both irreversible covalently binding BTK and BCL2 inhibitors, have worse outcomes than patients who have been treated with both drugs but have not developed resistance (double-exposed).

https://t.co/6YWFzDpz0b

#CLL #SLL #CLLSociety

[CLL Society Inc. @CllSociety]

Following its U.S. approval, BeOne Medicines’ BTK inhibitor is now available in a new tablet formulation for all approved indications, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Replacing the previous capsule form, the tablets are smaller, film-coated, and designed for easier swallowing. While recommended dosing remains the same, including flexible once- or twice-daily dosing, patients can now take two tablets rather than the four capsules, reducing their daily pill burden.

https://t.co/cAKfH8Ci40

#CLL #SLL #CLLSOCIETY

[CLL Society Inc. @CllSociety]

Your Medicare choices directly impact your CLL care. Don't make them alone.

July 22 is almost here. Legal experts Saira Sultan and Kay Scanlan will walk you through Medicare Part D in 2026, answer your specific questions, and help you understand how to protect your access to the medications you need.

This webinar is for anyone navigating Medicare and living with CLL. Whether you're newly eligible, switching plans, or trying to understand your current coverage, this is your moment to get clarity.

Because Smart Patients Get Smart Care™.
Register now: https://t.co/BZY0o3Hvjb

#CLL #Medicare #SmartPatientsGetSmartCare #Webinar

[CLL Society Inc. @CllSociety]

Choosing a CLL/SLL treatment can be challenging, especially as new therapies continue to emerge.

In thi

s educational video, two CLL experts explain the main types of targeted therapies, the factors that influence treatment selection, and how treatment decisions may evolve if CLL/SLL progresses.

Watch to gain a better understanding of treatment sequencing and become a more informed partner in your care. After viewing the video, be sure to complete the Test Your Knowledge questions to reinforce key concepts and check your understanding.

https://t.co/louJyGPprQ

#CLLSociety #CLL #SLL

[CLL Society Inc. @CllSociety]

Strong patient–nurse partnerships can make a meaningful difference throughout the CLL treatment journey. Learn practical strategies for patient education, treatment monitoring, and managing targeted therapies from @AmyGoodrich2018 and colleagues in this @PeerView activity.

Learn more: https://t.co/b32JI9iUuH

#CLL #BloodCancer #OncologyNursing

[CLL Society Inc. @CllSociety]

Your questions matter. Your perspective matters. Your voice matters.

On July 15 at 11am PT / 2pm ET, CLL Society is bringing together our community to ask the questions that matter most. Dr. Joanna M. Rhodes and patient advocate Jeff Folloder will be here to listen, answer, and engage in real conversation about living with CLL.

This is your space. Bring your questions. Share your experiences. Connect with others who understand what you're going through.

No question is too small. No concern is off limits. This is community.

Sign up and join us: https://t.co/86shnNEuud

#CLL #CommunityMatters #SmartPatientsGetSmartCare

[CLL Society Inc. @CllSociety]

Happy Fourth of July!

We hope you have a safe and memorable holiday celebrating with family, friends, and loved ones.

#CLLSociety

[CLL Society Inc. @CllSociety]

Our upcoming webinar brings you clarity on Medicare Part D. Understand your coverage options, protect your access to CLL medications and make informed decisions about your healthcare.

July 22 at 9am PT / 12pm ET, legal experts Saira Sultan and Kay Scanlan break down what patients need to know about Medicare Part D in 2026.

Sign up: https://t.co/BZY0o3Hvjb
#CLLSociety #CLL #Medicare #Webinar #SLL #Medicare2026 #MedicarePartD

[CLL Society Inc. @CllSociety]

What role do nurses play in helping patients navigate today's targeted treatment options in CLL?

Hear from @AmyGoodrich2018, Christina Baldwin, MSN, RN, NP-C, and Caitlin Murphy, DNP, APRN, FNP-BC, AOCNP, in this educational activity from @PeerView.

Watch now: https://t.co/b32JI9imF9